Stem Cell Transplant for Hemoglobinopathy
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | September 12, 2005 | ||||
Last Updated Date | April 10, 2012 | ||||
Start Date ICMJE | June 2002 | ||||
Estimated Primary Completion Date | June 2012 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Grade 3-4 Regimen Related Toxicity [ Time Frame: 1 year ] [ Designated as safety issue: Yes ] | ||||
Original Primary Outcome Measures ICMJE |
Efficacy is defined as continued neutrophil engraftment with at least 10% donor cells by d100. | ||||
Change History | Complete list of historical versions of study NCT00176852 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
|
||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Stem Cell Transplant for Hemoglobinopathy | ||||
Official Title ICMJE | Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism | ||||
Brief Summary | This study tests the clinical outcomes of one of two preparative regimens (determined by available donor source) in patients with non-malignant hemoglobinopathies. The researchers hypothesize that these regimens will have a positive effect on post transplant engraftment and the incidence of graft-versus-host-disease. Regimen A2 has replaced Regimen A in this study. Two patients were treated on Regimen A but did not have evidence of initial engraftment thus triggering the stopping rule for that arm of this study. |
||||
Detailed Description | Prior to transplantation, subjects will receive either: Cyclophosphamide, Fludarabine, Campath, Total body irradiation (TBI) Or Busulfan, Cyclophosphamide, antithymocyte globulin (ATG), granulocyte colony-stimulating factor (GSCF) These drugs (and the radiation) are being given to help the new stem cells take and grow. On the day of transplantation, subjects will receive stem cells transfused via intravenous (IV) catheter. After stem cell transplantation, subjects will be given cyclosporine-A and mycophenolate (MMF)/or Methylprednisone/or Methotrexate to reduce the risk of graft-versus-host disease, the complication that occurs when the donor's stem cells react against the patient. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 2 Phase 3 |
||||
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE |
|
||||
Study Arm (s) |
|
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE | 30 | ||||
Estimated Completion Date | June 2014 | ||||
Estimated Primary Completion Date | June 2012 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | up to 50 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE |
|
||||
Location Countries ICMJE | United States | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00176852 | ||||
Other Study ID Numbers ICMJE | MT2002-07, 0206M26241 | ||||
Has Data Monitoring Committee | Yes | ||||
Responsible Party | Smith, Angela R, Masonic Cancer Center, University of Minnesota | ||||
Study Sponsor ICMJE | Masonic Cancer Center, University of Minnesota | ||||
Collaborators ICMJE | National Marrow Donor Program | ||||
Investigators ICMJE |
|
||||
Information Provided By | Masonic Cancer Center, University of Minnesota | ||||
Verification Date | April 2012 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |